JP Morgan Maintains Neutral on UroGen Pharma, Lowers Price Target to $39

JP Morgan maintains UroGen Pharma (NASDAQ:URGN) with a Neutral and lowers the price target from $40 to $39.

Benzinga · 11/13/2019 13:54

JP Morgan maintains UroGen Pharma (NASDAQ:URGN) with a Neutral and lowers the price target from $40 to $39.